Indegene Ltd
NSE:INDGN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/GP
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Valuation Scenarios
If EV/GP returns to its Industry Average (8), the stock would be worth ₹0 (100% downside from current price).
| Scenario | EV/GP Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0 | ₹499.75 |
0%
|
| Industry Average | 8 | ₹0 |
-100%
|
| Country Average | 6.5 | ₹0 |
-100%
|
Forward EV/GP
Today’s price vs future gross profit
Peer Comparison
| Market Cap | EV/GP | P/E | ||||
|---|---|---|---|---|---|---|
| IN |
I
|
Indegene Ltd
NSE:INDGN
|
120B INR | 0 | 0 | |
| US |
G
|
GE Vernova LLC
NYSE:GEV
|
291.1B USD | 0 | 0 | |
| UK |
E
|
Eight Capital Partners PLC
F:ECS
|
158.4B EUR | 0 | 0 | |
| US |
C
|
China Industrial Group Inc
OTC:CIND
|
121B USD | 2 198.6 | 4 020.7 | |
| NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
100.2B ZAR | 13.2 | 10.4 | |
| US |
F
|
Fintech Ecosystem Development Corp
NASDAQ:FEXD
|
67.4B USD | 0 | 38 074.9 | |
| US |
C
|
CoreWeave Inc
NASDAQ:CRWV
|
56B USD | 0 | 0 | |
| CH |
G
|
Galderma Group AG
SIX:GALD
|
38.4B CHF | 0 | 0 | |
| US |
|
Coupang Inc
F:788
|
31.4B EUR | 3.1 | 173.5 | |
| US |
|
Symbotic Inc
NASDAQ:SYM
|
35.6B USD | 70.7 | -3 268.5 | |
| ZA |
V
|
Vukile Property Fund Ltd
JSE:VKE
|
29.7B ZAR | 14.8 | 6.9 |
Market Distribution
Other Multiples
Indegene Ltd
Glance View
Indegene Ltd. is an intriguing tale of how technology and healthcare can converge to redefine industry standards. Established in 1998, this Bangalore-based company has strategically positioned itself at the intersection of life sciences, digital marketing, and healthcare solutions. Indegene capitalizes on providing tailored solutions to pharmaceutical and healthcare companies, leveraging its unique expertise in analytics, research, and digital innovation. With the constant need for improved healthcare delivery and a more personalized patient experience, Indegene addresses these demands by offering a comprehensive suite of services that includes medical, marketing, and managed care solutions. It helps its clients to navigate the complexities of regulatory landscapes, optimize pharmaceutical commercialization, and harness the power of data-driven medical research. The financial engine behind Indegene's success lies in its ability to seamlessly blend domain expertise with digital prowess. The company generates revenue primarily through long-term contracts with some of the world's leading life sciences companies. By providing strategic insights and operational execution in areas such as content management, omni-channel marketing, and commercialization strategy, Indegene empowers its clients to optimize their business processes, engage more effectively with healthcare professionals, and ultimately enhance patient outcomes. Its investment in building proprietary platforms and cutting-edge technology tools has enabled it to offer scalable, efficient solutions that are both cost-effective and inherently innovative, ensuring that Indegene remains a pivotal player in the ever-evolving healthcare landscape.